Placebo News and Research

RSS

Study investigates use of sublingual immunotherapy against ragweed allergy

An international team of researchers, led by physician-scientists at Johns Hopkins, reports that a once-daily tablet containing a high dose of a key ragweed pollen protein effectively blocks the runny noses, sneezes, nasal congestion and itchy eyes experienced by ragweed allergy sufferers.

8 May 2013

Immunoglobulin fails to meet co-primary endpoints in Phase III clinical study, Baxter reports

Baxter International Inc. today announced that its Phase III clinical study of immunoglobulin did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease.

From Baxter International Inc. 8 May 2013

Study; Media reports about supposedly hazardous substances may trigger nocebo effect in some people

Media reports about substances that are supposedly hazardous to health may cause suggestible people to develop symptoms of a disease even though there is no objective reason for doing so.

7 May 2013

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

NI Research, the leading publisher of independent research on the neurotherapeutics industry, has released the May issue of NeuroPerspective, which reviews the status and prospects of therapeutics for Parkinson's.

7 May 2013

Oral drops provide a safe and effective alternative for allergy sufferers

Allergy shots are commonly used to treat children with severe environmental allergies and asthma, but under-the-tongue drops may offer yet another beneficial - and stick-free - option for pediatric allergy sufferers, according to a Johns Hopkins Children's Center review of existing scientific evidence.

6 May 2013

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.

4 May 2013

Vitamin C may decrease impact of smoking during pregnancy on childhood respiratory health

Pregnant women are advised not to smoke during pregnancy because it can harm the baby's lungs and lead to wheezing and asthma, among other problems. If a woman absolutely can't kick the habit, taking vitamin C during pregnancy may improve her newborn's lung function and prevent wheezing in the first year of life, according to a study to be presented Saturday, May 4, at the Pediatric Academic Societies (PAS) annual meeting in Washington, DC.

4 May 2013

Men who take statins are less likely to die from prostate cancer, study finds

Men with prostate cancer who take cholesterol-lowering drugs called statins are significantly less likely to die from their cancer than men who don't take such medication, according to study led by researchers at Fred Hutchinson Cancer Research Center.

3 May 2013

Study brings opportunities of personalised therapy for breast cancer a step closer

A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.

2 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

2 May 2013

AcelRx Pharmaceuticals reports clinical results of Sufentanil NanoTab PCA System for acute pain treatment

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported additional clinical results for its lead product candidate, the Sufentanil NanoTab PCA System for the treatment of moderate-to-severe acute pain in the hospital setting.

2 May 2013

Researchers study how ketamine reduces side effects of ECT in people with severe depression

The largest trial into the use of Electroconvulsive Therapy in the UK in more than 30 years will look into how the use of the Class C drug ketamine might reduce the side effects of ECT for those being treated for severe depression.

2 May 2013

Exclusion diet boosts anal fissure healing

Research published in the American Journal of Gastroenterology shows that an exclusion diet combined with medical treatment can increase healing rates in patients with chronic anal fissure who have been referred for surgery.

30 Apr 2013

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.

From Pfizer, Inc. 30 Apr 2013

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

29 Apr 2013

Opsona raises €33M in oversubscribed financing round

Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.

29 Apr 2013

NIH halts large clinical trial of HIV vaccine candidate

"The National Institutes of Health on Thursday halted a study testing an experimental HIV vaccine after an independent review board found the vaccine did not prevent HIV infection and did not reduce the amount of HIV in the blood," Reuters reports (Steenhuysen, 4/25).

29 Apr 2013

Ampio completes patient enrollment in dose-escalation run-in study of Ampion for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.

26 Apr 2013

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

26 Apr 2013

Placebo News and Research

Study investigates use of sublingual immunotherapy against ragweed allergy

Immunoglobulin fails to meet co-primary endpoints in Phase III clinical study, Baxter reports

Study; Media reports about supposedly hazardous substances may trigger nocebo effect in some people

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

Oral drops provide a safe and effective alternative for allergy sufferers

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Vitamin C may decrease impact of smoking during pregnancy on childhood respiratory health

Men who take statins are less likely to die from prostate cancer, study finds

Study brings opportunities of personalised therapy for breast cancer a step closer

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

AcelRx Pharmaceuticals reports clinical results of Sufentanil NanoTab PCA System for acute pain treatment

Researchers study how ketamine reduces side effects of ECT in people with severe depression

Exclusion diet boosts anal fissure healing

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Opsona raises €33M in oversubscribed financing round

NIH halts large clinical trial of HIV vaccine candidate

Ampio completes patient enrollment in dose-escalation run-in study of Ampion for treatment of knee osteoarthritis

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News